The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: Therapeutic implications

Leukemia Research

Volumn 37, Issue 4, 2013, Pages 465-472

  Quintás Cardama, Alfonso ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Combination therapies; JAK2 V617F; Janus kinase 2 (JAK2); Myelofibrosis; Myeloproliferative neoplasms

Indexed keywords

AZACITIDINE; GIVINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; INTERLEUKIN 6; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; LENALIDOMIDE; MITOGEN ACTIVATED PROTEIN KINASE; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PACRITINIB; PANOBINOSTAT; PHENYLALANINE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PRACINOSTAT; PROTEIN KINASE B; PROTEIN KINASE TYK2; RUXOLITINIB; SB 939; STAT3 PROTEIN; STAT5 PROTEIN; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANEMIA; ANTIANGIOGENIC ACTIVITY; ASYMPTOMATIC DISEASE; BLOOD TRANSFUSION; CARCINOGENESIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; ERYTHROCYTE TRANSFUSION; FATIGUE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HYPERAMYLASEMIA; HYPERLIPASEMIA; HYPOTENSION; JAK2 GENE; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NEUTROPENIA; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN FUNCTION; PRURITUS; REVIEW; SIGNAL TRANSDUCTION; SPLEEN SIZE; THROMBOCYTHEMIA; THROMBOCYTOPENIA;

ALLELES; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; JANUS KINASE 2; MICE; MUTATION; MYELOPROLIFERATIVE DISORDERS; PROTEIN KINASE INHIBITORS;

EID: 84875378326     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.12.006     Document Type: Review

References (61)

1. Radich J. The molecular biology of myeloproliferative disorders. Cancer Cell 2010, 18:7-8.
2. Hoffman R., Rondelli D. Biology and treatment of primary myelofibrosis. Hematology Am Soc Hematol Educ Program 2007, 346-354.
3. Lataillade J.J., Pierre-Louis O., Hasselbalch H.C., Uzan G., Jasmin C., Martyré M.C., et al. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. Blood 2008, 112:3026-3035.
4. Wernig G., Kharas M.G., Okabe R., Moore S.A., Leeman D.S., Cullen D.E., et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008, 13:311-320.
5. Pardanani A., Gotlib J.R., Jamieson C., Cortes J.E., Talpaz M., Stone R.M., et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 2011, 29:789-796.
6. Zou H., Yan D., Mohi G. Differential biological activity of disease-associated JAK2 mutants. FEBS Lett 2011, 585:1007-1013.
7. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
8. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
9. Dawson M.A., Bannister A.J., Göttgens B., Foster S.D., Bartke T., Green A.R., et al. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature 2009, 461:819-822.
10. Lasho T.L., Pardanani A., McClure R.F., Mesa R.A., Levine R.L., Gilliland D.G., et al. Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 2006, 135:683-687.
11. Pardanani A.D., Levine R.L., Lasho T., Pikman Y., Mesa R.A., Wadleigh M., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006, 108:3472-3476.
12. Wernig G., Mercher T., Okabe R., Levine R.L., Lee B.H., Gilliland D.G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006, 107:4274-4281.
13. Shide K., Shimoda H.K., Kumano T., Karube K., Kameda T., Takenaka K., et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia 2008, 22:87-95.
14. Xing S., Wanting T.H., Zhao W., Ma J., Wang S., Xu X., et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008, 111:5109-5117.
15. Akada H., Yan D., Zou H., Fiering S., Hutchison R.E., Mohi M.G. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010, 115:3589-3597.
16. Mullally A., Lane S.W., Ball B., Megerdichian C., Okabe R., Al-Shahrour F., et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010, 17:584-596.
17. Pikman Y., Lee B.H., Mercher T., McDowell E., Ebert B.L., Gozo M., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006, 3:e270.
18. Quintás-Cardama A., Kantarjian H., Cortes J., Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 2011, 10:127-140.
19. Hsiao H.H., Yang M.Y., Liu Y.C., Lee C.P., Yang W.C., Liu T.C., et al. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia. Exp Hematol 2007, 35:1704-1707.
20. Patriarca A., Pompetti F., Malizia R., Iuliani O., Di Marzio I., Spadano A., et al. Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients. Blood Transfus 2010, 8:21-27.
21. Campbell P.J., Griesshammer M., Döhner K., Döhner H., Kusec R., Hasselbalch H.C., et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006, 107:2098-2100.
22. Barosi G., Bergamaschi G., Marchetti M., Vannucchi A.M., Guglielmelli P., Antonioli E., et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007, 110:4030-4036.
23. Passamonti F., Rumi E. Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica 2009, 94:7-10.
24. Vannucchi A.M., Antonioli E., Guglielmelli P., Pardanani A., Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008, 22:1299-1307.
25. Antonioli E., Guglielmelli P., Poli G., Bogani C., Pancrazzi A., Longo G., et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008, 93:41-48.
26. Moliterno A.R., Williams D.M., Rogers O., Spivak J.L. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 2006, 108:3913-3915.
27. Passamonti F., Rumi E., Pietra D., Della Porta M.G., Boveri E., Pascutto C., et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006, 107:3676-3682.
28. Silver R.T., Vandris K., Wang Y.L., Adriano F., Jones A.V., Christos P.J., et al. JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res 2011, 35:177-182.
29. Passamonti F., Rumi E., Pietra D., Elena C., Boveri E., Arcaini L., et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010, 24:1574-1579.
30. Guglielmelli P., Barosi G., Specchia G., Rambaldi A., Lo Coco F., Antonioli E., et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood 2009, 114:1477-1483.
31. Tefferi A., Strand J.J., Lasho T.L., Knudson R.A., Finke C.M., Gangat N., et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007, 21:2074-2075.
32. Vannucchi A.M., Antonioli E., Guglielmelli P., Rambaldi A., Barosi G., Marchioli R., et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007, 110:840-846.
33. Lippert E., Girodon F., Hammond E., Jelinek J., Reading N.S., Fehse B., et al. Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 2009, 94:38-45.
34. Stein B.L., Williams D.M., Rogers O., Isaacs M.A., Spivak J.L., Moliterno A.R. Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients. Exp Hematol 2011, 39:95-101.
35. Quintás-Cardama A., Vaddi K., Liu P., Manshouri T., Li J., Scherle P.A., et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010, 115:3109-3117.
36. Jakafi (ruxolitinib) prescribing information 2011, Incyte Corporation, Wilmington, DE.
37. US Food and Drug Administration (FDA). FDA approves first drug to treat a rare bone marrow disease [press release]. Rockville, MD: US Food and Drug Administration; November 16, 2011. Available from:. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280102.htm.
38. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012, 366:799-807.
39. Verstovsek S., Mesa R.A., Gotlib J., Levy R.S., Gupta V., DiPersio J.F., et al. Consistent benefit of ruxolitinib over placebo in spleen volume reduction and symptom improvement across subgroups and overall survival advantage: results from COMFORT-I. Blood 2011, 118. [abstract 278].
40. Harrison C., Kiladjian J.J., Al-Ali H.K., Gisslinger H., Waltzman R., Stalbovskaya V., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012, 366:787-798.
41. Vannucchi A.M., Kiladjian J.J., Gisslinger H., Passamonti F., Al-Ali H.K., Sirulnik L.A., et al. Reductions in JAK2V617F allele burden with ruxolitinib treatment in COMFORT-II, a phase III study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT). J Clin Oncol 2012, 30. [abstract 6514].
42. Tefferi A., Litzow M.R., Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med 2011, 365:1455-1457.
43. Verstovsek S., Kantarjian H.M., Estrov Z., Cortes J.E., Thomas D.A., Kadia T., et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012, 120:1202-1209.
44. Pardanani A., Gotlib J.R., Jamieson C., Cortes J.E., Talpaz M., Stone R., et al. SAR302503: interim safety, efficacy and long-term impact on JAK2 V617F allele burden in a phase I/II study in patients with myelofibrosis. Blood 2011, 118. [abstract 3838].
45. Pardanani A., George G., Lasho T., Hogan W.J., Litzow M.R., Begna K., et al. A phase I/II study of CYT387, an oral JAK-1/2 inhibitor, in myelofibrosis: significant response rates in anemia, splenomegaly, and constitutional symptoms. Blood 2010, 116:460.
46. Pardanani A., Gotlib J.R., Gupta V., Roberts A.W., Wadleigh M., Sirhan S., et al. An expanded multicenter phase I/II study of CYT387, a JAK-1/2 inhibitor for the treatment of myelofibrosis. Blood 2011, 118. [abstract 3849].
47. Pardanani A., Caramazza D., George G., Lasho T.L., Hogan W.J., Litzow M.R., et al. Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis. J Clin Oncol 2011, 29. [abstract 6514].
48. ® annual meeting and exposition 2012.
49. Verstovsek S., Odenike O., Scott B., Estrov Z., Cortes J., Thomas D.A., et al. Phase I dose-escalation trial of SB1518, a novel JAK2/FLT3 inhibitor, in acute and chronic myeloid diseases, including primary or post-essential thrombocythemia/polycythemia vera myelofibrosis. Blood 2009, 114:3905.
50. Seymour F., To B., Goh A., Meadows L., Ethirajulu A., Wood A., et al. First report of the phase-I study of the novel oral JAK2 inhibitor SB1518 in patients with myelofibrosis. Haematologica 2010, 95(Suppl. 2):472. [abstract 1144].
51. Komrokji R.S., Wadleigh M., Seymour J.F., Roberts A.W., To L.B., Zhu H.J., et al. Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. Blood 2011, 118. [abstract 282].
52. Koppikar P., Bhagwat N., Kilpivaara O., Manshouri T., Adli M., Hricik T., et al. Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 2012, 489:155-159.
53. Hornakova T., Springuel L., Devreux J., Dusa A., Constantinescu S.N., Knoops L., et al. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. Haematologica 2011, 96:845-853.
54. Manshouri T., Estrov Z., Quintás-Cardama A., Burger J., Zhang Y., Livun A., et al. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res 2011, 71:3831-3840.
55. Wang Y., Fiskus W., Chong D.G., Buckley K.M., Natarajan K., Rao R., et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009, 114:5024-5033.
56. Baffert F., Evrot E., Ebel N., Roelli C., Andraos R., Qian Z., et al. Improved efficacy upon combined JAK1/2 and pan-deacetylase inhibition using ruxolitinib (INC424) and panobinostat (LBH589) in preclinical mouse models of JAK2V617F-driven disease. Blood 2011, 118. [abstract 798].
57. Rambaldi A., Finazzi G., Vannucchi A.M., Martinelli V., Rodeghiero F., Nobile F., et al. A phase II study of the HDAC inhibitor givinostat in combination with hydroxyurea in patients with polycythemia vera resistant to hydroxyurea monotherapy. Blood 2011, 118. [abstract 1748].
58. Quintás-Cardama A., Kantarjian H., Borthakur G., Estrov Z., Cortes J.E., Verstovsek S. Therapy with the histone deacetylase inhibitor Sb939 for patients with myelofibrosis. Blood 2011, 118. [abstract 3863].
59. Quintás-Cardama A., Kantarjian H.M., Manshouri T., Thomas D., Cortes J., Ravandi F., et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol 2009, 27:4760-4766.
60. Mesa R.A., Yao X., Cripe L.D., Li C.Y., Litzow M., Paietta E., et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 2010, 116:4436-4438.
61. Tefferi A., Cortes J., Verstovsek S., Mesa R.A., Thomas D., Lasho T.L., et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006, 108:1158-1164.